Abstract
Transthyretin amyloidosis (ATTR) is a progressive, systemic, and potentially fatal condition in which misfolded transthyretin proteins form amyloid deposits in muscle and organ tissue. Currently available disease modifying ATTR-related pharmacotherapies generally slow or stop the progression of disease and the benefit of early initiation of treatment has been demonstrated. These analyses examine the relationship between time-to-treatment following symptom onset and long-term patient-reported outcomes (PROs) in patients with ATTR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
